Nitroglycerin Extended-Release Capsules (Glyceryl Trinitrate) 2.5 mg & 6.5 mg

Nitroglycerin, known in Australia as glyceryl trinitrate, is one of the oldest and most studied medicines used in cardiovascular care. We offer it as an oral extended-release capsule in 2.5 mg and 6.5 mg strengths, a form designed for the ongoing prevention of angina rather than for the rapid relief of an attack already under way. This article explains what the capsule contains, how it works in the body, how it is generally used, and how our ordering process and delivery within Australia fit around it.

Because nitroglycerin is available in several quite different forms - sublingual tablets, sprays, transdermal patches, ointments and this extended-release oral capsule - understanding exactly which product and release type you are looking at matters. Everything below relates specifically to the oral extended-release capsule we list, at 2.5 mg and 6.5 mg, and not to the fast-acting sublingual or spray products used for an acute anginal episode.

What Nitroglycerin Extended-Release Capsules Are

The active ingredient is glyceryl trinitrate, an organic nitrate ester that has been used in cardiovascular medicine since the 1870s. Our capsules are an oral, extended-release dosage form designed to release the active ingredient gradually as it moves through the gastrointestinal tract, rather than releasing it all at once. This is quite different from a sublingual tablet or spray, which is designed to act within minutes but only for a short period. The extended-release design exists to provide a steadier, longer-lasting anti-anginal effect suited to prevention rather than to rescue treatment of chest pain that has already started.

We currently list this capsule in two strengths, 2.5 mg and 6.5 mg, so that a prescriber's chosen regimen can be matched to an appropriate pack. Pack sizes range from 30 up to 360 capsules, which lets a customer align an order with the length of therapy a doctor has recommended, whether that is a short trial period or an ongoing supply.

Angina Pectoris and Coronary Artery Disease

Angina pectoris is the chest discomfort, tightness or pressure that occurs when the heart muscle's demand for oxygen outstrips the blood supply the coronary arteries can deliver, most commonly because of narrowing from atherosclerosis. Typical angina is triggered by exertion, emotional stress, cold exposure or a heavy meal, and it generally eases with rest. Chronic stable angina reflects fixed narrowing of one or more coronary arteries, while unstable angina reflects an acute worsening of plaque or blood flow and is a medical emergency in its own right. Long-acting nitrate therapy, including the extended-release capsule form, is used within the broader management of chronic stable angina, generally alongside other measures such as beta-blockers, calcium channel blockers, antiplatelet therapy, lipid management, and risk-factor control for blood pressure, smoking and diabetes.

How Nitroglycerin Works in the Body

Nitroglycerin is a prodrug. Once absorbed, it is converted enzymatically - largely by mitochondrial aldehyde dehydrogenase in vascular smooth muscle - into nitric oxide. Nitric oxide activates soluble guanylate cyclase inside the smooth muscle cell, raising levels of cyclic GMP and triggering relaxation of vascular smooth muscle. The effect is most pronounced in veins, where it produces venodilation that reduces the volume of blood returning to the heart (preload), lowering the workload the heart must perform. At higher exposure it also dilates arteries, including the coronary arteries themselves, redistributing blood flow towards oxygen-starved areas of heart muscle and modestly reducing the resistance the heart pumps against (afterload). The net effect is a reduction in myocardial oxygen demand and an improvement in the oxygen supply-to-demand balance that underlies an anginal episode.

This mechanism explains both the medicine's usefulness and its most common side effects. The same smooth muscle relaxation that eases the heart's workload also dilates blood vessels in the skin and meninges, which is why flushing and headache are so frequently reported, and why a drop in blood pressure with light-headedness can occur, particularly on standing.

Evidence Behind Long-Acting Nitrate Therapy

Organic nitrates have a clinical record stretching back well over a century, and their anti-anginal effect through venous and arterial dilation is well established pharmacologically. What the evidence base has also shown clearly is a phenomenon called nitrate tolerance: with continuous, unbroken nitrate exposure, the haemodynamic and anti-anginal effect can diminish within roughly 24 to 48 hours through several proposed mechanisms, including neurohormonal counter-regulation and changes affecting nitrate bioactivation. This is why long-acting nitrate regimens, including extended-release oral capsules, are generally built around a nitrate-free or lower-exposure interval each day, typically planned by the prescribing doctor rather than left to chance. Oral nitroglycerin also undergoes extensive first-pass hepatic metabolism, giving it lower and more variable bioavailability than isosorbide mononitrate, which is one reason prescribers weigh the oral extended-release capsule against other long-acting nitrate options when planning a regimen.

Formulation and Active Ingredient

Each capsule we list contains glyceryl trinitrate as the sole active ingredient, formulated as an extended-release oral preparation rather than an immediate-release or sublingual product. The two strengths we carry, 2.5 mg and 6.5 mg, allow a prescriber to titrate a dose within the oral extended-release class specifically, distinct from the very different milligram ranges used for sublingual tablets, transdermal patches or intravenous infusions, which are not interchangeable on a milligram-for-milligram basis with this capsule.

What This Medicine Is Used For

The established use of this oral extended-release capsule is the prevention of angina pectoris associated with coronary artery disease, taken on a regular schedule set by a prescriber to reduce the frequency of anginal episodes over time. It is not intended, and is too slow in onset, to relieve chest pain during an acute attack; sublingual nitroglycerin tablets or spray remain the appropriate fast-acting option for that purpose, and a person prescribed the extended-release capsule for prevention will often also be given a fast-acting form for breakthrough symptoms, on their doctor's advice.

Strengths, Pack Sizes and General Dosing Principles

We offer this capsule in 2.5 mg and 6.5 mg strengths, in packs of 30, 60, 90, 120, 180, 270 or 360 capsules, so that a customer can match an order to the exact quantity a prescriber has recommended. A commonly labelled adult starting range for extended-release oral nitroglycerin is 2.5 mg to 6.5 mg three or four times daily, with the dose and timing then adjusted according to symptom control and tolerability. Because continuous nitrate exposure promotes tolerance, the prescribing doctor should plan a daily nitrate-free or lower-exposure interval appropriate to the formulation and the person's pattern of angina. These are general educational principles rather than a specific regimen for any individual reader, and the exact dose, timing and duration should always follow the applicable product instructions and the prescribing doctor's directions. The capsules should be swallowed whole with water rather than chewed or crushed, since damaging an extended-release capsule can disrupt its intended release pattern. Instructions about whether to take a particular product with or without food should be followed consistently because they may vary by formulation.

Elimination and Half-Life

Nitroglycerin itself has a very short plasma half-life, typically in the order of only a few minutes, because it is rapidly metabolised - largely in the liver and within vascular tissue - to dinitrate and mononitrate metabolites, some of which retain weaker vasodilator activity and a somewhat longer half-life than the parent compound. These metabolites are further broken down and eliminated mainly via the kidneys. The extended-release capsule formulation exists precisely because the parent drug disappears from the circulation so quickly: gradual release continues delivering nitroglycerin over several hours, allowing the formulation to sustain an effect that would otherwise vanish within minutes of a plain oral dose being absorbed.

Important Safety Information

Nitroglycerin's blood-vessel-relaxing effect is also its main safety concern. It can cause a meaningful drop in blood pressure, particularly when standing up quickly, after drinking alcohol, or in someone who is already dehydrated or on other blood-pressure-lowering medicines. Dizziness, light-headedness, fainting and blurred vision have all been reported, and these effects can impair a person's ability to drive or operate machinery, so caution is warranted, especially when a dose is started or increased. This medicine has not had its safety and effectiveness established in children, and its use in pregnancy should only occur if a doctor judges it clearly necessary after weighing the potential benefit against any risk, since human pregnancy data for the extended-release oral form remain limited. It is not known whether nitroglycerin passes into breast milk, so caution is advised for a breastfeeding parent under a doctor's guidance. People with a known allergy to nitrates or to any capsule ingredient should not take this medicine, though an unrelated or unspecified allergy history is not, on its own, a reason to avoid it.

Prescription Status and How to Order With Us

Oral glyceryl trinitrate capsules used for angina are classified as Schedule 4 prescription medicines in Australia, meaning that, as a matter of local regulation, a prescriber's involvement is expected for this medicine generally. Separately, as a matter of our own ordering process, we do not require a prescription to be uploaded before we accept an order for this listing, and our pharmacist-supported team is available around the clock by email, online chat or phone to talk through any question before or after you order. These are two distinct facts: the medicine's classification in Australia, and the document we ask for at our own checkout, and we keep them separate rather than treating one as evidence of the other. A current TGA registration for this exact glyceryl trinitrate capsule product and each listed strength has not been confirmed, so check the Australian Register of Therapeutic Goods for the specific brand, strength and dosage form; PBS availability and subsidy conditions likewise depend on the specific product and indication. Our listing describes the exact glyceryl trinitrate capsule, strengths and pack sizes we currently supply.

Who Should Not Take Nitroglycerin

Nitroglycerin extended-release capsules are contraindicated for anyone with known hypersensitivity to nitrates, nitroglycerin or any capsule ingredient. They must not be combined with phosphodiesterase type 5 inhibitors such as sildenafil, tadalafil or vardenafil, or with the soluble guanylate cyclase stimulator riociguat, because the combination can cause a severe, potentially life-threatening drop in blood pressure. Careful prescriber assessment is also required for people with severe anaemia, raised intracranial pressure, marked hypotension, shock or severe uncorrected hypovolaemia, as well as those with right ventricular infarction, hypertrophic obstructive cardiomyopathy, constrictive pericarditis or cardiac tamponade, because nitrate-induced venodilation may worsen their condition. A full medical history is the appropriate way to identify whether any of these apply, which is why prescriber input remains important even when a document is not required at the point of ordering.

Interactions With Other Medicines and Substances

The most important interaction is with phosphodiesterase type 5 inhibitors and with riociguat, as noted above, which is treated as an absolute contraindication rather than a caution. Alcohol can add to nitroglycerin's blood-pressure-lowering effect and increase the risk of dizziness or fainting. Other antihypertensive medicines, other vasodilators, and diuretics can compound the hypotensive effect and may require dose or timing adjustments that a prescriber will manage. Nitroglycerin is often used alongside beta-blockers or calcium channel blockers as part of a broader anti-anginal plan, a combination that is common and generally well tolerated under medical supervision, though it still calls for monitoring of blood pressure and heart rate. Anyone taking other prescription medicines, over-the-counter products or supplements should mention them to a prescriber or pharmacist so a full interaction check can be carried out.

Side Effects and When to Act

Headache is the most frequently reported side effect of nitroglycerin therapy and is often dose-related; it tends to ease as treatment continues but can be a reason some people cannot tolerate higher doses. Flushing, dizziness, and a mild drop in blood pressure are also common, particularly early in treatment or after a dose increase. Nausea and light-headedness on standing occur in some people.

Less common but more serious effects call for prompt medical attention. These include fainting or a marked, sustained drop in blood pressure, a rapid or irregular heartbeat, chest pain that feels different from a person's usual pattern or does not settle with rest and their prescribed fast-acting nitrate, and signs of an allergic reaction such as facial or throat swelling, widespread rash or difficulty breathing. A person experiencing severe or persistent symptoms, or chest pain that does not resolve, should seek urgent medical care or call an ambulance without delay.

Overdose and Toxicity

An overdose of nitroglycerin is primarily a cardiovascular event, driven by excessive vasodilation. Expected features include profound hypotension, reflex tachycardia, intense headache, flushing, visual disturbance, nausea, vomiting, dizziness and, in severe cases, circulatory collapse or loss of consciousness. At high exposure, nitroglycerin can also cause methaemoglobinaemia, in which haemoglobin loses its normal oxygen-carrying capacity, producing a bluish discolouration of the skin and lips along with fatigue and shortness of breath. Management is generally supportive: lying the person flat with legs raised to support blood pressure, intravenous fluids where needed, and close monitoring, with methylene blue used specifically to treat significant methaemoglobinaemia when it occurs. Anyone who has taken more than their prescribed dose, or who develops these symptoms, should seek emergency medical care immediately or contact the Poisons Information Centre for guidance.

Storage

Store these capsules at 20°C to 25°C, in their original, tightly closed container, protected from light and moisture, and out of reach of children. Nitroglycerin is sensitive to heat, humidity and air exposure, all of which can degrade the active ingredient over time, so the container should not be left open longer than necessary and the capsules should not be transferred into an unsealed pillbox for extended periods. Any capsules that are out of date, discoloured, or otherwise appear compromised should not be used.

Benefits and Trade-offs

The main benefit of the extended-release oral capsule is convenient scheduled dosing aimed at reducing the background frequency of angina, rather than relying on repeated doses of a fast-acting nitrate for prevention. Its trade-offs relate largely to nitrate tolerance and to variable oral bioavailability from first-pass liver metabolism, both of which mean the anti-anginal effect can be less predictable across a full day compared with careful use of a transdermal patch with a defined patch-off period, or with isosorbide mononitrate, which is metabolised differently. It also does not replace a fast-acting sublingual tablet or spray for an actual anginal episode, since its onset is too gradual for that purpose. Choosing between these forms is a decision for a prescriber based on a person's pattern of angina, other medicines, and how well tolerance-related effects are managed with a nitrate-free interval.

Generic Equivalents and Alternative Treatments

Glyceryl trinitrate is the active ingredient name used in Australia for nitroglycerin, and any product using either name with the same dosage form, strength and release characteristics is considered a generic equivalent rather than a different medicine. Several other nitroglycerin-based products exist internationally in different forms, including sublingual tablets, translingual sprays, transdermal patches and topical ointments, none of which are directly interchangeable with this oral extended-release capsule on a dose-for-dose basis because their absorption and duration of action differ substantially.

Beyond nitroglycerin itself, other long-acting nitrates such as isosorbide dinitrate and isosorbide mononitrate work through the same nitric oxide pathway and are often considered alongside oral extended-release nitroglycerin when planning angina prevention, generally with somewhat more predictable bioavailability. Non-nitrate anti-anginal options, including beta-blockers such as metoprolol and calcium channel blockers, work through different mechanisms and are frequently combined with a long-acting nitrate rather than used strictly as substitutes for it. A prescriber is best placed to weigh these options against a person's specific pattern of angina, other health conditions and current medicines, and we are glad to have our pharmacist team on hand by phone, chat or email if a customer has questions about how our available strengths and pack sizes fit whatever plan their prescriber has set.